doripenem has been researched along with ciprofloxacin in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimoto, S; Ike, Y; Okuzumi, K; Tanimoto, K; Tomita, H | 1 |
| Bell, JM; Castanheira, M; Jones, RN; Mathai, D; Turnidge, JD | 1 |
| Bulik, CC; Crandon, JL; Nicolau, DP | 1 |
| Aquino, EE; León, CF; Otero, DM; Robledo, IE; Santana, JL; Santé, MI; Vázquez, GJ | 1 |
| Choi, JY; Ko, KS; Lee, MY; Park, YK; Peck, KR; Rhee, JY; Shin, JY; Song, JH | 1 |
| Carmeli, Y; Chmelnitsky, I; Goren, MG; Navon-Venezia, S | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fernando, DM; Gorityala, BK; Goswami, S; Guchhait, G; Kumar, A; Schweizer, F; Zhanel, GG | 1 |
| Bojkovic, J; Dean, CR; Dobler, M; Dzink-Fox, J; Glick, M; Hamann, LG; Kerrigan, J; Lanieri, L; Lenoir, F; Lilly, MD; Liu, E; Lu, Y; McKenney, D; Nunez, J; Osborne, C; Parker, DT; Patnaik, A; Peng, Y; Piizzi, G; Ranjitkar, S; Sprague, ER; Tommasi, R; Wang, B; Wang, H; Wattanasin, S; Xie, L; Yang, X; Yu, D | 1 |
| Flamm, R; Friedland, I; Kaniga, K; Lee, M; Redman, R; Tong, SY | 1 |
| Anan, N; Ito, A; Nakamura, R; Toba, S; Tsuji, M | 1 |
| Firsov, AA; Gilbert, D; Greer, K; Portnoy, YA; Zinner, SH | 2 |
| Davies, TA; He, W; Lynch, AS; Queenan, AM | 1 |
| Barnett, AG; Diab, S; Fraser, JF; Fung, YL; Roberts, JA; Shekar, K; Wallis, SC | 1 |
| Goto, K; Itoh, H; Kai, M; Kitano, T; Ohchi, Y; Suzuki, Y; Tanaka, R; Tatsuta, R; Yasuda, N | 2 |
1 review(s) available for doripenem and ciprofloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
17 other study(ies) available for doripenem and ciprofloxacin
| Article | Year |
|---|---|
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
Topics: Base Sequence; beta-Lactam Resistance; Carbapenems; DNA Primers; DNA, Bacterial; Doripenem; Fluoroquinolones; Genes, Bacterial; Humans; In Vitro Techniques; Meropenem; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2008 |
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
Topics: Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Humans; India; Microbial Sensitivity Tests; Molecular Sequence Data; Prevalence; Pseudomonas aeruginosa; Ribotyping | 2009 |
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Administration Schedule; Female; Humans; Mice; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Detection of KPC in Acinetobacter spp. in Puerto Rico.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Aged; Aged, 80 and over; beta-Lactam Resistance; beta-Lactamases; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance; Puerto Rico | 2010 |
KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
Topics: Aged; beta-Lactamases; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Klebsiella Infections; Klebsiella pneumoniae; Male; Renal Dialysis; Republic of Korea | 2010 |
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
Topics: Academic Medical Centers; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; DNA Primers; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Humans; In Vitro Techniques; Israel; Microbial Sensitivity Tests; Molecular Epidemiology; Plasmids; Time Factors | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2016 |
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Chemistry Techniques, Synthetic; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Female; Hep G2 Cells; Humans; K562 Cells; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship | 2017 |
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Ciprofloxacin; Clinical Trials, Phase III as Topic; Doripenem; Enterobacteriaceae; Enterobacteriaceae Infections; Global Health; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence | 2010 |
[In vitro combination effects of doripenem with aminoglycoside or ciprofloxacin against Pseudomonas aeruginosa].
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Ciprofloxacin; Doripenem; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tobramycin | 2011 |
Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model.
Topics: Anti-Bacterial Agents; Area Under Curve; Carbapenems; Ciprofloxacin; Doripenem; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Models, Biological; Mutation; Predictive Value of Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model.
Topics: Anti-Bacterial Agents; Carbapenems; Ciprofloxacin; Doripenem; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Time Factors | 2013 |
Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Carbapenems; Ciprofloxacin; Doripenem; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Synergism; Drug Therapy, Combination; Female; Levofloxacin; Mice; Ofloxacin; Pneumonia, Ventilator-Associated; Random Allocation; Survival Analysis | 2013 |
Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.
Topics: Animals; Anti-Infective Agents; Carbapenems; Caspofungin; Ceftriaxone; Ciprofloxacin; Critical Illness; Doripenem; Echinocandins; Extracorporeal Membrane Oxygenation; Fluconazole; Gentamicins; Lipopeptides; Meropenem; Models, Theoretical; Sheep; Sheep, Domestic; Thienamycins; Vancomycin | 2015 |
Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Azoles; Carbapenems; Chromatography, High Pressure Liquid; Ciprofloxacin; Daptomycin; Doripenem; Drug Monitoring; Female; Fluconazole; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Linezolid; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Oxazines; Oxazolidinones; Quinolones; Tandem Mass Spectrometry; Tetrazoles; Voriconazole | 2021 |
UHPLC-MS/MS method for simultaneous quantification of doripenem, meropenem, ciprofloxacin, levofloxacin, pazufloxacin, linezolid, and tedizolid in filtrate during continuous renal replacement therapy.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Continuous Renal Replacement Therapy; Doripenem; Humans; Levofloxacin; Linezolid; Meropenem; Tandem Mass Spectrometry | 2023 |